Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

MAY 17, 2019

During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. But such tools only work when companies play fair.

Pricing 79

Pricing Competition Tool Marketing 79

Xconomy

MAY 31, 2019

[ Corrected 5/31/19, 8:48 am ET. Pharmaceutical companies that make or market opioids have found themselves in legal hot water, and much of the heat is coming from Oklahoma. This week, a trial began litigating Johnson & Johnson’s responsibility for opioid addiction in the Sooner State.

Marketing 67

Marketing San Diego Company Companies 67